Early diagnosis and treatment of prostate cancer

2001 ◽  
Vol 47 (9) ◽  
pp. 418-459 ◽  
Author(s):  
James A. Eastham ◽  
Peter T. Scardino
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Diagnosis And Treatment

Early Diagnosis and Treatment of Localized Prostate Cancer

2001 ◽  
Vol 40 (3) ◽  
pp. 361-370 ◽  
Author(s):  
C.H. Bangma ◽  
H. Huland ◽  
F.H. Schröder ◽  
P.J. van Cangh
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Diagnosis And Treatment ◽  
Localized Prostate Cancer

scholarly journals Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Symmetry ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 974
Author(s):  
Md. Abu Rayhan ◽  
Md. Sakib Hossen ◽  
Mahruba Sultana Niloy ◽  
Mozammel Haque Bhuiyan ◽  
Sudip Paul ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Iron Oxide ◽  
Early Diagnosis ◽  
Anticancer Agents ◽  
Early Stage ◽  
Treatment Strategies ◽  
Fine Tuning ◽  
Diagnosis And Treatment ◽  
Theranostic Agents

Prostate cancer (PCa) is the most common malignancy in men and the leading cause of death for men all over the world. Early diagnosis is the key to start treatment at an early stage of PCa and to reduce the death toll. Generally, PCa expresses characteristic morphologic features and serum biomarkers; however, early diagnosis is challenging due to its heterogeneity and long-term indolent phase in the early stage. Following positive diagnosis, PCa patients receive conventional treatments including surgery, radiation therapy, androgen deprivation therapy, focal therapy, and chemotherapy to enhance survival time and alleviate PCa-related complications. However, these treatment strategies have both short and long-term side effects, notably impotence, urinary incontinence, erectile dysfunctions, and recurrence of cancer. These limitations warrant the quest for novel PCa theranostic agents with robust diagnostic and therapeutic potentials to lessen the burden of PCa-related suffering. Iron oxide nanoparticles (IONPs) have recently drawn attention for their symmetrical usage in the diagnosis and treatment of several cancer types. Here, we performed a systematic search in four popular online databases (PubMed, Google Scholar, Scopus, and Web of Science) for the articles regarding PCa and IONPs. Published literature confirmed that the surface modification of IONPs with biopolymers and diagnostic biomarkers improved the early diagnosis of PCa, even in the metastatic stage with reliable accuracy and sensitivity. Furthermore, fine-tuning of IONPs with biopolymers, nucleic acids, anticancer drugs, and bioactive compounds can improve the therapeutic efficacy of these anticancer agents against PCa. This review covers the symmetrical use of IONPs in the diagnosis and treatment of PCa, investigates their biocompatibility, and examines their potential as PCa theranostic agents.

Role of exosomes in diagnosis and therapy of prostate cancer

2020 ◽  
Vol 28 (3) ◽  
pp. 399-405
Author(s):  
Fabrizio Fontana ◽  
Olga A. Babenko
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Biological Fluids ◽  
Diagnosis And Treatment ◽  
Diagnosis And Therapy ◽  
The Future ◽  
Important Direction ◽  
Potential Biomarkers

Aim of this letter is to attract the attention of journal readers to the study of exosomes as an important direction in the development of Oncology, in particular, in the diagnosis and treatment of prostate cancer. Exosomes are produced by tumor cells and regulate proliferation, metastasis, and the development of chemoresistance. Their extraction from biological fluids allows further use of these vesicles as potential biomarkers of prostate cancer. In the future, exosomes can be successfully used in the delivery of drugs and other anti-tumor substances to cancer cells.

Sign in / Sign up

Export Citation Format

Share Document